1. Home
  2. MPLT vs HQH Comparison

MPLT vs HQH Comparison

Compare MPLT & HQH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MPLT

MapLight Therapeutics Inc.

N/A

Current Price

$28.57

Market Cap

1.3B

Sector

Health Care

ML Signal

N/A

Logo abrdn Healthcare Investors Shares of Beneficial Interest

HQH

abrdn Healthcare Investors Shares of Beneficial Interest

HOLD

Current Price

$19.50

Market Cap

1.1B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
MPLT
HQH
Founded
2018
1986
Country
United States
United States
Employees
133
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance Companies
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.1B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
MPLT
HQH
Price
$28.57
$19.50
Analyst Decision
Strong Buy
Analyst Count
7
0
Target Price
$32.67
N/A
AVG Volume (30 Days)
253.4K
124.3K
Earning Date
05-28-2026
01-01-0001
Dividend Yield
N/A
11.56%
EPS Growth
N/A
N/A
EPS
N/A
1.09
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$17.93
Revenue Growth
N/A
N/A
52 Week Low
$12.24
$15.09
52 Week High
$33.28
$20.46

Technical Indicators

Market Signals
Indicator
MPLT
HQH
Relative Strength Index (RSI) 52.37 46.28
Support Level $26.70 $18.61
Resistance Level $32.23 $19.62
Average True Range (ATR) 2.34 0.39
MACD -0.40 -0.10
Stochastic Oscillator 58.24 31.56

Price Performance

Historical Comparison
MPLT
HQH

About MPLT MapLight Therapeutics Inc.

MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.

About HQH abrdn Healthcare Investors Shares of Beneficial Interest

abrdn Healthcare Investors Formerly Tekla Healthcare Investors is the United States based non-diversified closed-end management investment company. Its objective is to seek long-term capital appreciation by investing in securities of healthcare companies. In addition, the fund seeks to provide regular distribution of realized capital gains. The fund invests in the securities of public and private companies.

Share on Social Networks: